This study aims to evaluate the safety and tolerability of JPI-547 in combination with irinotecan as a third-line and beyond therapy for recurrent or metastatic gastric cancer
Patients with recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma who have progressed after second-line therapy.
Those with Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Those with at least one measurable lesion in accordance with RECIST 1.1
Patients with a confirmed specific medical history or past surgical history
Patients who meet specific criteria regarding prior treatment
Patients with a history of specific drug administration
Patients with specific comorbidities.